Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

ZyVersa Therapeutics, Inc. (ZVSA)

Compare
0.5873
-0.0002
(-0.03%)
At close: April 2 at 4:00:00 PM EDT
0.5801
-0.01
(-1.23%)
After hours: April 2 at 6:07:52 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ZVSA

Recent News: ZVSA

View More
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire 6 days ago
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
GlobeNewswire 15 days ago
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
GlobeNewswire 21 days ago
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
GlobeNewswire 27 days ago
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
GlobeNewswire 28 days ago
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
GlobeNewswire 3 months ago

OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR
Zacks Small Cap Research 4 months ago
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
GlobeNewswire 4 months ago
Life Sciences Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum: Presentations Now Available for Online Viewing
GlobeNewswire 4 months ago
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
GlobeNewswire 4 months ago
Life Sciences Investor Forum Agenda Announced for November 14th

Life Sciences Investor Forum Agenda Announced for November 14th
GlobeNewswire 4 months ago
View More

Related Tickers

SPRC SciSparc Ltd.
0.3040
+5.96%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.3449
-4.19%
 
REVB Revelation Biosciences, Inc.
2.6700
+1.52%
 
PXMD PaxMedica, Inc.
0.0002
0.00%
 
ENSC Ensysce Biosciences, Inc.
2.6400
+5.60%
 
BDRX Biodexa Pharmaceuticals Plc
1.5400
+28.33%
 
PALI Palisade Bio, Inc.
0.6676
-0.33%
 
TVGN Tevogen Bio Holdings Inc.
1.0700
-1.83%
 
VRAX Virax Biolabs Group Limited
1.1400
+5.56%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.2925
+37.52%